Business Wire

PJSC-MAGNITOGORSK-IRON-A

6.6.2022 16:43:13 CEST | Business Wire | Press release

Share
PJSC Magnitogorsk Iron and Steel Works: MMK notifies on initiation of bondholders’ consent solicitation process

MMK notifies on initiation of bondholders’ consent solicitation process 06 JUNE 2022 Magnitogorsk, Russia PJSC Magnitogorsk Iron & Steel Works (MOEX: MAGN; LSE: MMK) notifies on initiation of bondholders’ consent solicitation process ("Consent Solicitation").

PUBLIC JOINT STOCK COMPANY MAGNITOGORSK IRON & STEEL WORKS (the “Guarantor”)

with respect to the U.S.$500,000,000 4.375 per cent. Guaranteed Notes due 2024 issued by MMK INTERNATIONAL CAPITAL DAC (the “Issuer”)

(the “Notes”)

(ISIN: XS1843434959 (Regulation S) / US553142AA88 (Rule 144A); Common Code: 111730628 (Regulation S) / 111730628 (Rule 144A Common code))

issued by the Issuer and unconditionally and irrevocably guaranteed by Public Joint Stock Company Magnitogorsk Iron & Steel Works

Due to blocking restrictions introduced by the EU and UK, breakdown in transaction functionality between the EU and Russian clearing systems and currency controls introduced by the Russian authorities, payments of interest made by the Guarantor for the benefit of the Noteholders may get blocked, frozen or delayed for an uncertain period of time by the clearing systems or other entities processing those payments.

The Guarantor assures that:

  1. it has sufficient financial resources and is making every effort to effect payment of interest due to the Noteholders as soon as processing of payments could be assured;
  2. for the purposes of receiving the licenses from the relevant US, UK and Irish authorities which are required to ensure the due exercise of rights and obligations in relation to the Notes compliant with all applicable sanctions, it is now preparing documents for filings with the relevant authorities.

Considering the foregoing, the Issuer and the Guarantor are initiating a Consent Solicitation and invite Noteholders to agree to certain amendments and/or waivers to the terms of the Notes for the purposes of ensuring the due and punctual performance in relation to the Notes and in order to protect the rights and interests of the Noteholders.

The Guarantor encourages the Noteholders to liaise with its Investor Relations department and/or Rybalkin, Gortsunyan, Dyakin and Partners Advocates Bureau (“RGD”) directly to obtain a copy of the Consent Solicitation Memorandum and to discuss other related matters.

All documentation relating to the Consent Solicitation, together with any updates, will be available upon request to RGD at MMKconsentsolicitation2022@rgd.legal . In your communique, please also confirm the aggregate notional amount of the Notes that you hold and the location of the depository.

Noteholders may contact RGD via email at MMKconsentsolicitation2022@rgd.legal if they require assistance. Should the Noteholders have any additional questions, please contact with the Guarantor’s Investor Relations department via email at: ir@mmk.ru .

ISIN: US5591892048
Category Code: MSCM
TIDM: MMK
LEI Code: 253400XSJ4C01YMCXG44
Sequence No.:

166355

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye